Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Agios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for Agios Pharmaceuticals, Inc..
OpenMomentus says its cash position has jumped to about $76 million with no debt. The real question is whether Vigoride progress can become revenue before share-count math absorbs the upside.
OpenA beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenA source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenA beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenDatavault AI's June 4 Form 8-K turns the structured financing story into a cash, dilution, control, and approval proof gate.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAlpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, s
OpenTag facets appear after tag usage counts are rebuilt.